---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-25-000023"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2025-04-23T23:59:59+00:00"
generated_at: "2026-05-23T08:45:29.366658+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific Q1 sales $4.66B (+20.9% reported, +18.2% organic), EPS beat guidance

## Summary
- GAAP EPS $0.45 (up 36% YoY); adjusted EPS $0.75, above guidance $0.66-0.68.
- Cardiovascular segment sales grew 26.2% reported (25.6% organic); MedSurg +11.7% reported (+5.3% organic).
- U.S. sales up 31.1%; EMEA +5.5%, APAC +8.2%, LACA +4.4%.
- FY2025 outlook: organic +12-14%, adj. EPS $2.87-$2.94; Q2: organic +13-15%, adj. EPS $0.71-$0.73.
- Closed Bolt Medical acquisition; agreed to acquire SoniVie Ltd. for TIVUS hypertension denervation technology.

## SEC filing metadata
- accession: 0000885725-25-000023
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2025-04-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572525000023/0000885725-25-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572525000023/bsx-20250423.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-25-000023
- JSON: https://secwatch.observer/filing/0000885725-25-000023.json
- Plain text: https://secwatch.observer/filing/0000885725-25-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.